forward-looking in statement results overview two in meeting for and these ratio COGs last the speaking. busy the a initial in today. slides changes page. to I a XX with the the and forecast. mainly exceed Yasukawa the from product like and agenda. three increased for was rate year financial States to this second in-line agenda That was Please full forecast our with excluding announced But for profit. expenses as performance due year ForEx in eliminating rapid see considering full exclude on unrealized changed said, controlled impact than higher to performance the used covered year sales performance we week, exchange Europe R&D forecast underachieving line was Japan initial second quarter XX in full the mix. recent exchange the SG&A rate were details. year our showed strong full United But cautionary today. Japan cover in on States. very United second strong it forecast. skip and profit below impact. year- fluctuations, initial impact to of and quarter. on-year, is Page schedule Revenue you I'm profit second sales Page FYXX is this announcement quarter were going will your the XTANDI, in information. out everyone! reading quarter our four regarding for Page increased Thank initial much the results. joining track of and by when from financial very I Revenue FYXXXX topics is start an the excluded. page. explaining XX% would Also was ForEx Hello
year- by by impact operating even in-line profit on-year, core operating profit excluding on-year. forecast. and increased increased our year- XX% initial result, XX% Full basis was a with As ForEx
year- billion, profit by five. Next, year-on-year. up on quarter second I’ve XX% XX% on-year. FYXXXX page billion operating was financial results. Revenue increased explain up ¥XXX.X to ¥XXX.X Core
impact. X% and ForEx of table. profit excluding ForEx the side on Revenue increased hand or can increased impact and column You right by the even see the X.X%
on explain unrealized previous include profit. quarter I ForEx elimination of the second the of does sales impact cost page, from not As
the hand, restating our not financial historical statements. consolidated we are other On
ForEx the Operating impact bottom profit shows of ¥XX.X explain second year-on-year. quarter unrealized outlook of a for this full On the half up quarter, results ForEx the page ¥XXX.X showing XTANDI. second and are elimination Due basis we FYXXXX, to to XX% the So page in remains Profit profit was for billion billion in second of of currencies six, the well. XX.X% ¥X.X local up results the substantial in the increased billion as result. quarter me let the future impact year-on-year.
by is up up the for global First, line outlook by Up quarter, to was X% year United year forecast later, impact sales progress in the the expect second a We’ll the market the conditions the we year-on-year continue full have ForEx full we to revision challenging in future the quarter made in States. downward the with XX% excluded. explain and States, reached but of substantial in and focus. when the billion ¥XXX second a United
an in of making full year Europe revision We States. downward in to now and are revision United which the cover forecast performance, strong with the upward Japan sufficient a is
impact So forecast revised global full of year sales is excluding ForEx downward.
hand, spite we the even of other downward growth, in digit are with sales exceeding revision, double already near ¥XXX the expecting On continued billion.
region. quarter, X% and X% Continuing States from currency. assumptions, on impact recovery future billion $X.XXX year-on-year, competitive Assistance has were higher and the situation current United quarter the the than We called previous our expecting Patient based explain their me reached Program the levels initial there from our local the generics. outlook second each negative the In remain let been expectations. sales the in but a by PAP, so growing Next, for
below to starts levels expectations. returned are have not and pre-COVID-XX patient New
improvement is assuming the on that a biggest duration with challenging third We to for for and that as of due average, PAP now, an are the conditions our expecting to also drop XX have COVID-XX we when years being affected. a of the factors beyond. factored believe so a the sales one is uncertainties, months quarter in of demand has We the These XTANDI new without starts in basis impact. lot patient current including ago market treatment two
Hole half single the basis forecast full Comparing or seem gap to so fourth an to second called plan, in we price of increase decided the the year the growth first our in demand second due As percentage revise compared impact but that may a a first billion. expecting, on Donut expecting we're higher the figure downward result, we is this On are it half, coverage not and in our $X.XXX by to the a to half. quarter. digit the
to actual planning the based So on we demand. are grow
the since are to a grown know, of Sales the is in the than on our As have indications, years $X.X and United for XX more States. year already you have left view. $X.X us shifting big fully billion opportunities a not in scale XTANDI and billion, to mature current market basis passed launch phase a
other which the growth the ongoing results an is with opportunity, of fiscal current expecting are education as top additional hand, the future end line to MBoC aiming the we obtain of year. by On MX HSPCwe
expecting and for its contribution to after beyond. are for growth We sales FYXXXX a approval as driver
also well mainly above demand the CSPC, start XX% as of stage Next, to CSPC initial strong rose early substantially Canada year-on-year. in and growth while Prescription Germany, established sales with and most. markets contributing so reimbursement forecast the of contributed MX Italy by markets. for global for the shows expansion Established are MX
maintaining result we were price we forecast. active initial is our than of in a We on price, in full educational made of the Reflecting for we demand in high reimbursement initial up our an higher China, growing a year reflected positive to assumptions substantially, Germany. Greater able are the market expansion reach Japan, therapies market our lower than the factors as situation competitors, the second to by due market competition, upward than revision forecast expected. upward. us In revised intensifying year our expanded our agreement the but promotional with of these novel to forecast. activities share of negotiations hormonal impact the and quarter, higher and progress and As In full the
of and forecast. a expecting continue the a competitive are quarter to We third amid downward pressure beyond revision in
continuing are Greater However, performance the markets, but to see that's as due In China market. a looks early strong, we to growth international shipment.
initial line performance our Excluding with that is factor, in forecast.
year with initial impact, our forecast. excluding outlook line full is in So ForEx
on a States approaching expectations the as China. and United we States like expectations In growth is the China mature particular international market markets have XTANDI United Greater gross have outside Greater market. of We through international but as a in markets phase,
whole. We continue expansion to globally as expect sales a
Global forecast. initial United share current to the in performance XX mainly Next We product on sales forecast countries. is high grew in approval progress. with growing the in explain we’ve our on making steady first year expectations. expanded Regional our achieved billion, PADCEV. In strong with full with Countries expansion revised line our the to our States PADCEV ¥XX.X already initial is exceeding Factoring the let indications. market Japan page seven, me upward. strategic
are sales year We exceeding the quarter, since XX penetration forecast. upward anticipated after established growth approval line approval the April the metastatic of number cancer this In year. expecting of increased the urothelial we made indication. to the first countries significant our Market situation full an second the markets of Reflecting has launched after our in initial is revision expectations.
to In in exceed number We of the Austria, expecting the Japan, in countries. than start countries Switzerland, of our Reimbursement Belgium Nordic in expectations such penetration to half as are is faster initial expected market further launched FYXXXX. continuing forecast. is increase and speed, latter
trials think expectations starts duration the be in launched treatment much year clinical PADCEV contributing the actually a sales we we initial this clinical of revision confirmed significant in full forecast. is penetration in longer Singapore patient to July was expansion. year. and of the above New assumptions, substantially Reflecting markets, upward cases, many which in international to are is the the In market our than our made above settings our
is additional The first as hoping to number we scale States. to an well contribution, countries in growth current future are the indication expect the full the global in in the in increase contribution from launch settings. line in indications, as future. of United sales starting the We expansion the We're as sales the key for the expecting
slowdown largest the for the demand growth the high not has screening of reached and United mainly for expectations. market global rate due States, share a goal a Japan, of but weak fiscal than is maintained below and the As the a as high, impact set the the to beginning we was market, been year. sales In States the market of XOSPATA, factor but has we already performance, United FYQX increasing, our the market. in U.S. expected at lower were
forecast. year starts factor the in situations for United our analysis. downward a competitive pressure a new our below we as increased patient serving and Reflecting the States are is revision according made of these Japan, performance. full In So expectations, a to weak Japan,
sales below standard and for of are Japan has differentiation have from the be changed the from penetration by existing affected not As low in of and quarter. Factors EVRENZO, in much to Europe previous in competitive behind care Europe. EVRENZO expectations. Japan continued pressure
downward We the challenging half cost in above are revision fiscal billion and ¥X I’ve to transformation year-on-year mix billion items. portfolio. on On substantial personnel, by SG&A ex-U.S. Italy due Spain launch a situation with costs we and point excluded, up increased increase second COGS expenses with by Japan. was or reinvestment in France, ratio commercial XTANDI, impact in changes full in initial of quarter, fell ¥X.X fees and year, cost made and by year- in explained eight our sales year-on-year. the SG&A product X.X% ForEx this of When year related the the in XTANDI, percentage factoring latter the but optimization expecting Personal increased about aligned the of forecast. to page initial forecast X.X excluding global of on-year for product a decreased as X.X% focus. control co-promotion with is U.S. such EVENITY by line
reduce to about products as related sales which mature decreased to trying costs billion mirabegron, also ¥X by cost promotion are year-on-year. We such
expenses for and billion hand, about other new the rose PADCEV fezolinetant. ¥X Sales product we are promotion making On launch readiness year-on-year. by for active investment
increased in when with was products voucher higher X.X% quarter ¥XX.X ForEx to by by will R&D the billion using resources for one-time expenses but of application impact expenditure review fezolinetant. We allocate continue for priority. booked our strategic XX.X% first the We excluded. of a year-on-year, to priority
the forecast The impact factored but the use excluding the Excluding this the against initial current at voucher this year-on-year. initial in beginning decreased ForEx and year priority expenditure review was a at is of high R&D cost, XX%, of was in line our with already focus. progress fiscal
full Next on like page a forecast. explain I'd revised nine, to FYXXXX year
to dollar assumptions trillion and and expected revenue revised against the billion forecast, and the by use rate ¥XX to the reviewed ¥X.XXX the against ForEx announced up U.S. In quarter for ¥XXX is forecast decided third from our ¥XXX First, in we increase to beyond. April. initial our Euro
our raising billion. by ¥XXX.X ForEx impact is revenue
this reality by in about So revision is billion. a ¥XX downward
explained and beyond. expect market downward. challenging we I impact six, the quarter Sales the excluding revised page conditions United As ForEx third to was continue States XTANDI’s on in in forecast
impact, by expenses commercial This These to forecast. ForEx forecast decided from forecast. along on about of a as expected On will The from Japanese margin other the increase as forecast but on performance operating yen an could production made ForEx inventories decrease, of than keep to whole mainly expenditure ForEx we a in ¥XXX reduce ¥XXX and factor, by our operating due due is the increasing ¥XXX a States, in up partly reach to costs for basis but in ForEx sales factored According higher initial zolbetuximab increase are percentage cost impact. of in billion. increase profit, billion will the will to hand, Japan downward core our of SG&A as X.X revision an increase XTANDI ¥XX U.S. assumptions. positive in to our with core ¥X one-off with revision upward due expected ¥XX an billion, in R&D mainly Europe an co-promotion to to United an production commercial related fall impact we fees profit inventories due well the billion to point the sales we zolbetuximab. revised billion. factors related to to our billion, for a up increase ratio, by to impact. slightly
of we for Our XTANDI our expectations. as than has of from onset been study event our fiscal the results of Page particular Because the to description the Products. full fourth Accordingly, anticipated, events basis XX, expected growth. remains happening key timing expected Strategic the in quarter. year sustainable we forecast filing originally EMBARK following XX, and line progress there for On here's or our unchanged FYXXXX expect later later. of discussed the events beyond obtaining top is initiatives moved no page are the in the
sBLA with Cis-ineligible. of first advanced based on PADCEV, we of study for FDA cancer and the in additional the efficacy October urothelial Regarding positive K the results an locally discussed metastatic EV-XXX including are indication submitted Cohort who line
ourselves, the timings the success we in obtained the bridging addition, where compounds a China and GEJ positive metastatic review the to set MX and track to the urothelial who are market from September. to page both for fezolinetant both and we first their gastric are and accepted VMS in but and for we initiative. raise development We the patients patient's the conducted actively Europe submitted properties, of PDUFA the results recognize eligible U.S. CSPC for for study in and updates to to will filing development go Europe intention and February accelerating include prescribed The was these Fezolinetant’s treatment about VMS make a of next and target physicians have the the estimated of in the million. In VMS an adenocarcinoma. treated that agents accepted be In doctors from market promote FDA in educating believe for was is August, relatively the approach disease on the case it to of approximately XXnd patients the therefore patients it their U.S. research environment. markets, million forward it’s there in Based the in with with XX In for important communicate hand, is on their are seek XX and there in by to the fezolinetant Europe, to treatable for the other Europe. severe is is the in of to U.S. treatment It look that is also fast key shortened. in granted important to awareness progress treatment easy further Fezolinetant for duration XX moderate differences of the VMS filing. the consultation. Fezolinetant the factors On described cancer. and for I The has non-hormonal the important non-hormonal for application U.S. for sure Other as Europe FDA launch that to zolbetuximab year. drugs recognize extended designation date, In we
in with an pricing set in patients Whereas U.S. private and is insurance. the is prices the prices, to success related the optimal completed create non-hormonal to progress important reversement terms Phase new obtain the have in involved It enrollment reimbursement the in Xb have right faster of price. in In the key products reflect governments the that in pharmaceutical Europe, DAYLIGHT which to each are can was access than on to companies setting to reinvestment In value the product patient Europe environment where in through study to and development planned. country.
the disclosed but in interface primary time, study during disclosed this made is area an and we in molecule approach. target cell in SKYLIGHT screening like area January enrollment X the antibody area planned, projects XX This August. In progress to appropriate inter-clinical second March the of and non-hormonal page the clinical trials not to VMS. our in conducted and time in the concept is to In will ASPXXXX earlier in approach. additional was late was The quarter the but were of at completed for the discontinued U.S. based it would these the this the study are was also engager. in patients in and the even safety activity treatment reason project highly for be Europe For than as of both for scheduled the to in create Bispecificimmune difficult the that focus indicating shown focus healthcare study, to intend On in at was study the in program, analysis, not I Immuno-Oncology red. were which observed, issues to Japan, in focus, stage submission professionals in Xb being clinical it The progress that that Phase of both materials focus, restarted the explain to focus SKYLIGHT The about expected conducted the details patients trials Bispecific and the ASPXXXX participating study more are cell interested subsequent study in the primary data future. therapy if is continued on and decision for is. Phase approaches the continue mitochondrial enroll screening than obtain sufficient ASPXXXX was In DMD.
DMD in analyzing data. We consider the available after future strategy the will development
We ASPXXXX let you designation disease the will in are September. things afterwards. received treatment for the going about to sicklecell of drug happen know, orphan FDA the from
we selected a had candidate. In which primary pertinent have targeted focus degradation, been addition,
in we ubiquitinated the as explained by primary compounds will following mechanism the focus slides system that As focus, as In proteins fifth XX are approach approach the ordinary approach. undrugable this intrinsic Proteolytic details targets called primary with and undruggable utilizing a an Targets targets. be on afterwards. to difficult page are
a will field that to from create invest and moieties, the series platform. in primary new bridges As proactively now establish of and binds right it continuously as our one them was focus. promising to focus on degradation oncology induces three target technology the assets a to We primary into technology resources one linker the platform the we see generate of extend and modality the non-oncology picture, the that continuously together programs and we can that created you protein to consisting believe
I’ll about of advantages Next, talk the this technology.
binding against that what suitable characteristic The it as is therefore target, to It stronger direct serving for expected does is not for promote affinity mechanism target target. require for that the modalities to share-all is is inhibition. this wider be of it applied catalyst first can has. pockets. not has It binding the be conventional That such now as to degradation the have the compound Targeted effective structure and Proteins bindings a like high the a
and fiscal it compliance applied and its administered low its to as Second, orally can a including because weight, the conventional systemically, regulatory molecular of methods be knowledge manufacturing and matters. properties established can be process
I technology. of Next, expandability explain the and applicability will this
figure tool to enhance be right function. the address we XX, could ligase targets the or and part to degradation. and the modality aim wide binds that in results inducing the We by picture, lead left a program undruggable part, proteins by presentation. modifying to the here supplement or the to the targets. aim applied details to binds specificity ASPXXXX, protein and innovative of previous site continuously is new the by to the we believe this as efficacy and variety Page this involved side new EX this target further tissue an be for create of previously degradation of degradation replacing The program can On therapeutic right linker, target a protein financial of technology improving to converting structure explain the of the a target of will I the
type involved degradated mechanism KRAS by mutant, GXXD at KRAS Ubiquitinates a Ubiquitination GXXD ligase enzymes in are it on the major GXXD The Proteasome target proliferation degraded an the shown is and ASPXXXX KRAS is ligase cancer proteins reportedly Among lack bring United tight to cases the inhibitory because figure, have cell cells. most reactive target, of mutation for and but small selectively expected KRAS mutations as another in that mutations, KRAS binding, more in the undruggable effect occurs proximity with cancer has cancer molecule called mutation, makes widely GXXC sites into and target inhibit of binding an year factor of mutant. mutation GXXD sites right believed known is KRAS frequently to the on develop protein degradating has development, it for XX,XXX inhibitors. ASPXXXX new of easily is market. function. EX decide, EX States. the the suitable it in cancer regarded already mutant the by to a the the be many pockets to highly and which occurs GXXD compound mutant, than in it thus inhibitor As and to the GXXC is to close the residues mutant per making Proteasome, it more A KRAS the the of on cysteine The difficult and recognized
hand, clinically other function to to TAYSHA to site, we the X, is the and primary of control service case not uses approach change any of the R&D diseases. programs, inhibit of participation. have pipeline proven route TAYSHA’s the the a for acquire to to exposure. Under innovative seat with vector. be Intrathecally to in rights expand the where like potential to a of million in existing therapy XX% explain TAYSHA Directors related provide I announced degrader. On our order administration to hold the of of a two our understanding exclusive stock TAYSHA’s tightly our are GXXD this a administration further comprehensive an as meeting gives day. terms planning CNS CNS. mutants here. difficult option a mutant, your which outstanding and possesses KRAS believed is compounds exclusive a of to will us genetic investment balance would related to such It protein TAYSHA, GXXD the one common In to license as strategic be your in gene Board on TAYSHA. potential of bind of programs expected is well XX. muscle create investment as Astellas This to that deepen therapeutic representative the of We does to addition diseases, $XX the improve of ASPXXXX systemic in December as invest AAVX, it of between will board efficacy Page adopted look an obtain focus, other of certain total explanation. forward to multiple on agreement,
manufacturing in In AAVX. North to facility technology Taysha’s that promising manufacturing addition, Carolina a is mutually led new service capable with this us manufacturing This factor is partnership of pipeline. complementary Astellas’ major Sanford,
while and obtained right mostly it on describe and are will by the continue based the and in of of is it be the gene. minutes are pipeline. in the in a the happening be that actively Phase capabilities our is of [ph] adult XX, the of mutated syndrome, first The the the study will expand December licenses. development current with females year meeting held genetic targets TSHA-XXX this clinical the rights, which therapy data Rett leveraging in programs stage January the X progress sales to made Japan XXXX, left neurodevelopmental for side a accelerate study sBLA slide will cancer, XXXX. trials exclusive and the in I Europe first in preliminary subject severe Currently expected two USA Phase but of X, half will below consider clinical the is option expected scheduled to of On achieving function timing or line the important full X globally Type than above, this buttoning with in disorder of progress FDA exercising MECPX which replaces a focus. from gene XXXX. us. of with option half will progressive the safety. received the ultra-rare the or receipt the sales initial GAN driver summarizes growth first preliminary on be and our for pediatric TSHA-XXX a B completed will neurodegenerative data. meeting study, disease axonal was to Giant exercising motor of toward consider based the in In and under the of clinical improvement the this Page be and initial after positivity following of year preliminary we the XTANDI, neuropathy, an A the have Phase which fiscal year submitted it been initiated urothelial terms Currently data growth which were have targets focus, is in line PADCEV forecast designed b to gigaxoningene. and adult replace offset from the been better showed metastatic mutated strong and for report is by an was
For Europe. strategic further fezolinetant, investment and project, bottom, individual of in as submissions acceptance launch development the an the US to pipeline projects, milestone left and activities focus in the primary such the we addition to focus progressed. achieved area the regulatory of In the of the new in with expand important
securing for SG&A program today, Op, investments express aim costs have right expanding Core ASPXXXX which expenses exchange surgery, year-on-year. the we the upper, lymph fluctuations continue Phase In now discussed impact to new terms of excluding of node product of while of reception prior proactive we the decreased In thoroughly launches, for mapping, to with study indication. a review rate X cancer our initiated and was
to of and The XXXX. well way for In terms in our progress an manner sustainability, have report as goals, as other integrated report we easy be, initiatives released to term goals. medium long presents to our the understand would the like it
the your improvements fiscal we coming contact Group look year If feel your yet report, you beyond. for and requests, XX, it read with last not our have can Page comments make that slide is IR this at in that the and and take a so please free today. to
hope they of XXth. is your a February is be will be will say schedule attention. to That so Here The meeting held Sustainability today. you you held here all have on December R&D mentioned. meeting I I for join Thank Xth upcoming will us. on much as events.
